Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection-Reference-Cited by-同舟云学术

Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection

Published:2021-05-28 Issue:3 Volume:41 Page:581-586
ISSN:2096-5230
Container-title:Current Medical Science
language:en
Short-container-title:CURR MED SCI

Author:

Ahmed Manar,Mansey Azza E.,Wahsh Engy A.,Gomaa Ahmed A.,Rabea Hoda M.

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Biochemistry

Link

https://link.springer.com/content/pdf/10.1007/s11596-021-2363-9.pdf

Reference31 articles.

1. Kandeel A, Genedy M, El-Refai S, et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int, 2017,37(1):45–53

2. Gower E, Estes C, Black S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol, 2014,61(1 Suppl):S45–S57

3. Wahsh EA, Hussein AK, Gomaa AA, et al. Real life Egyptian experience of daclatasvir plus sofosbuvir with Ribavirin in Naïve difficult to treat HCV patients. Infect Disord Drug Targets, 2020,20(1):43–48

4. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol, 2017,66(1):153–194

5. Ahmed H, Ahmed E, Abushouk AI, et al. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis. Antivir Ther, 2017,22(5):369–379

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4;Current Drug Safety;2023-05

2. Therapeutic potential of pyrrole and pyrrolidine analogs: an update;Molecular Diversity;2022-01-25